An Open-Label, Multi-Center, Phase I Study I Study to Evaluate the Safety, Tolerability, Pharmacokinetic/Phamacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants With Locally Advanced or Metastatic Breast Cancer
Latest Information Update: 25 Jul 2024
At a glance
- Drugs GNC 035 (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- Sponsors Sichuan Baili Pharmaceutical
- 18 Jul 2024 Planned End Date changed from 1 Jun 2024 to 1 Oct 2024.
- 18 Jul 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Oct 2024.
- 05 Feb 2024 Planned End Date changed from 30 Nov 2023 to 1 Jun 2024.